Carnosine: Side Effects

Safety Overview#

Carnosine has a favorable safety profile based on its status as an endogenous compound, its long history as a dietary supplement, and data from multiple clinical trials. At standard supplementation doses of 1-2 g/day, carnosine is well tolerated with minimal adverse events. Side effects primarily emerge at single doses above 10 g.

Clinical Trial Safety Data#

Standard Doses (1-2 g/day)#

In the randomized controlled trials evaluating carnosine for diabetes and cognitive function:

• Houjeghani et al. (2018): 1 g/day for 12 weeks in 27 T2D patients. No specific adverse events attributed to carnosine supplementation were reported.
• de Courten et al. (2024): 2 g/day for 14 weeks in 43 prediabetes/T2D patients. No adverse events during the intervention period.
• Cognitive function trials: 1 g/day for 12 weeks. Well tolerated in elderly subjects and MCI patients.

Dose-Escalation Safety Data#

A pharmacokinetic and safety study in healthy volunteers tested escalating single doses:

Long-term dosing at 5 g twice daily did not result in adverse events, suggesting that chronic lower-dose regimens are better tolerated than high single doses.

Side Effect Details#

Gastrointestinal Effects#

Mild GI symptoms (nausea, diarrhea) are the most commonly reported side effects at standard doses. These are generally transient and may be reduced by taking carnosine with food. The incidence is low at 1-2 g/day and increases at higher doses.

Blood Pressure Effects#

Carnosine ingestion has been associated with decreases in both systolic and diastolic blood pressure, with the greatest reductions observed at doses of 4 g and above. For most people, this effect is neutral to beneficial. However, individuals taking antihypertensive medications or those with naturally low blood pressure should be aware of this potential interaction.

Paresthesia#

The tingling sensation (paresthesia) observed at high doses is likely attributable to the beta-alanine component released upon carnosine hydrolysis. Beta-alanine is well documented to cause transient paresthesia, primarily in the face, neck, and dorsum of hands, at single doses above 800 mg. This effect is benign and self-limiting, typically resolving within 60-90 minutes.

Drug Interaction Considerations#

Diabetes Medications#

Carnosine has demonstrated glucose-lowering effects in clinical trials. Individuals taking insulin, metformin, sulfonylureas, or other glucose-lowering medications should monitor blood sugar levels when initiating carnosine supplementation, as additive effects on glycemic control are possible.

Antihypertensive Medications#

The blood-pressure-lowering effect of carnosine may be additive with antihypertensive drugs. Blood pressure monitoring is advisable when combining carnosine with antihypertensive therapy.

Zinc and Mineral Interactions#

Carnosine chelates divalent metal ions including zinc and copper. Zinc-carnosine (Polaprezinc) is a specific chelate used therapeutically in Japan for gastric ulcer protection. While standard carnosine supplementation is unlikely to cause clinically significant mineral depletion, individuals with marginal zinc status should be aware of this interaction.

Special Populations#

Pregnancy and Lactation#

There are insufficient safety data to recommend carnosine supplementation during pregnancy or breastfeeding.

Pediatric Use#

Carnosine has been studied in children with autism spectrum disorder at doses of 400-800 mg/day. While generally well tolerated in these limited studies, pediatric use should be supervised by a healthcare provider.

Renal Impairment#

Carnosinase activity and carnosine metabolism may be altered in renal disease. The CNDP1 gene polymorphism is associated with susceptibility to diabetic nephropathy. Patients with significant renal impairment should consult a healthcare provider before supplementation.

Related Reading#

• Carnosine overview and research guide
• Carnosine dosing protocols
• Carnosine risks and legal status